Related Experiment Video
Updated: Aug 16, 2026
09:42
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
Published on: June 4, 2021
Tirofiban-Associated Thrombocytopenia: A Case Report
Mohamed Hassan1, Ayatullah Hegazy2, Aya Majwal3
1Intensive Care Unit, Mediclinic City Hospital, Dubai, ARE.
Cureus
|August 15, 2026
Summary
Tirofiban-induced thrombocytopenia is a rare but serious complication in acute coronary syndrome (ACS) patients. Prompt recognition and management are crucial for safe recovery and revascularization.
Area of Science:
- Cardiology
- Hematology
- Pharmacology
Background:
- Tirofiban is a glycoprotein IIb/IIIa inhibitor used in high-risk acute coronary syndrome (ACS).
- Thrombocytopenia is a potential adverse effect of tirofiban therapy.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...